A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 and 754111

The effect of prenatal administration of different doses of cortisone, corticosterone, dexamethasone, triamcinolone and prednisolone on the fetus and its palatal development was studied. All the glucocorticoids, except cortisone, produced cleft palate in the fetuses. Both the total frequency and morphologically different types of cleft palate were related to the dose of the teratogen. Triamcinolone appeared to be more potent than other glucocorticoid in inducing cleft palate. An association was noted between fetal growth inhibition, the dose of the teratogen and the frequency and type of cleft palate.

Download Full-text

Rubber Modified Asphalt Storage Stabilizer Option

Advanced Materials Research ◽

10.4028/www.scientific.net/amr.311-313.1136 ◽

2011 ◽

Vol 311-313 ◽

pp. 1136-1139

Author(s):

Zhong He Chen ◽

Zheng Qian Zhang ◽

Hua Lin Luo ◽

Ning Ning Dong

Keyword(s):

Storage Stability ◽

Experimental Methods ◽

Modified Asphalt ◽

The Poor ◽

Different Types ◽

And Storage ◽

Different Doses

In order to improve the poor compatibility and storage stability of rubber modified asphalt,authors using theoretical and experimental methods, to investigate the influence of the stabilizer on the storage stability and the using performance of rubber modified asphalt, through adding the different types and different doses of stabilizer, to improve its storage stability and using performance of modified asphalt.

Download Full-text

Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors

The Cancer Journal ◽

10.1097/ppo.0000000000000322 ◽

2018 ◽

Vol 24 (4) ◽

pp. 153-162 ◽

Cited By ~ 3

Author(s):

Florence Koeppel ◽

Alexandre Bobard ◽

Céline Lefebvre ◽

Marion Pedrero ◽

Marc Deloger ◽

...

Keyword(s):

Cancer Patients ◽

Solid Tumors ◽

Advanced Cancer ◽

Transcriptome Sequencing ◽

Added Value ◽

Advanced Cancer Patients ◽

Whole Exome

Download Full-text

The teratogenic effects of hydrocortisone on palatal development in the hamster

Development ◽

10.1242/dev.35.1.213 ◽

1976 ◽

Vol 35 (1) ◽

pp. 213-224

Author(s):

Ravindra M. Shah ◽

Anthony A. Travill

Keyword(s):

Cleft Palate ◽

Close Association ◽

Fetal Growth Retardation ◽

Placental Barrier ◽

Teratogenic Effects ◽

Different Types ◽

Palatal Development ◽

Two Peaks ◽

Different Doses ◽

Hydrocortisone Treatment

The effect of different doses of hydrocortisone, administered at various times during gestation, on the fetal hamster and its palatal development was studied. Both the frequency of cleft palate and that of resorption depended upon the dose of hydrocortisone and the time of its administration. Two peaks in the incidence of cleft palate were observed, which appeared to be due to inhibition of different events. Incidence of morphologically different types of cleft palate was related to the doses and gestational time of hydrocortisone treatment. A close association was observed between the frequency of cleft palate and fetal growth retardation and between the latter and the dose and time of drug administration. It was suggested that maternal physiology and the placental barrier may play a crucial role in cleft palate induction.

Download Full-text

Symptom Assessment and Early Access to Supportive and Palliative Care for Patients With Advanced Solid Tumors in Mexico

Journal of Palliative Care ◽

10.1177/0825859719834920 ◽

2019 ◽

Vol 35 (1) ◽

pp. 40-45 ◽

Cited By ~ 3

Author(s):

Mirza Jacqueline Alcalde-Castro ◽

Enrique Soto-Perez-de-Celis ◽

Alfredo Covarrubias-Gómez ◽

Sofía Sánchez-Román ◽

Paulina Quiróz-Friedman ◽

...

Keyword(s):

Palliative Care ◽

Supportive Care ◽

Solid Tumors ◽

Advanced Cancer ◽

Symptom Assessment ◽

First Year ◽

Advanced Solid Tumors ◽

Care Clinic ◽

Care Services ◽

Oncology Care

Background: Early specialized palliative care improves quality of life of patients with advanced cancer, and guidelines encourage its integration into standard oncology care. However, many patients fail to obtain timely palliative/supportive care evaluations, particularly in limited-resource settings. We aimed to determine the proportion of patients with advanced cancer who received an assessment of symptoms and were referred to supportive and palliative care services during the first year after diagnosis in a Mexican hospital. Methods: Individuals with newly diagnosed advanced solid tumors and 1 year of follow-up at the oncology clinics in the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran in Mexico City from October 2015 to April 2016 were included in this retrospective study. Results: Seventy-seven patients were included. Forty-two (54.5%) were referred to the various supportive care services during the first year after diagnosis, and 23 (29.8%) were referred to the palliative care clinic. The most commonly assessed symptoms by oncologists were pain (77.9%), anorexia (74.0%), fatigue (68.8%), and nausea (55.8%), while depression/anxiety were evaluated in 10 (12.9%) patients. The oncologist offered to clarify treatment goals in 39 (50.6%) cases and evaluated the understanding of diagnosis/illness and prognosis in 22 (28.5%). Conclusion: Palliative and supportive care services were widely underutilized, which may be related to a lack of standardized symptom assessments and poor end-of-life communication. Novel strategies are needed to improve the implementation of tools for systematic symptom assessment and to optimize the integration of supportive care interventions into oncology care in developing countries.

Download Full-text

Chemoprevention and epigenetic multitargeted approach.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.3_suppl.e297 ◽

2016 ◽

Vol 34 (3_suppl) ◽

pp. e297-e297

Author(s):

M. A. Nezami

Keyword(s):

Solid Tumors ◽

Advanced Cancer ◽

Histone Deacetylases ◽

Epigenetic Therapy ◽

Significant Shift ◽

Breast Cancers ◽

Suppressor Genes ◽

Preliminary Results ◽

Epigenetic Modifiers

e297 Background: In 2012 there were 11,957,599 advanced cancer cases in the US reported by CDC and the incidence has been almost unchanged over the previous 8 years (482,000 cases in 2000 versus 456,000 cases in 2008). There has been an annual percentage change of only (-0.6) between years 1999 to 2008 in cancer incidence. It is described in recent literature that epigenetic alterations are at least if not more important than genetic defects for the development and progression of malignant diseases. Transcriptional therapy is a very promising form of cancer treatment that is being extensively evaluated. It is speculated that inhibitors of DNA methylation and histone deacetylases can reactivate expression of tumor suppressor genes. Hypermethylation and transcription silencing of suppressor genes has been shown in 33% of breast cancers, 60% of prostate CA and 92% of colon CA. The value of combination therapy both in chemoprevention, as well as treatment in patients with cancer is extremely important and can cause a significant shift in the current practice of oncology and cancer prevention, the results in clinical studies have been poor as the target histone hyperacetylation does not correlate with survival (possibly due to P 16/21 resistance and unselectiveness of the conventional therapies/targets). Methods: In vitro application of epigenetic modifiers, consisting of nontoxic natural substances tested in cell cultures showed preliminary results confirming apoptosis. Application of the relevant scientific merits described above, using combination of epigenetic modifiers, and natural compounds in a protocol called Multi targeted epigenetic therapy (MTET) in a set of advanced patients showed synergistic effect which was clinically relevant. Results: Clinical application of this method of treating cancer has caused promising preliminary results. We present the summary of outcomes in one hundred cases of advanced cancer (refractory solid tumors) with thirteen cases, described in detail. Conclusions: Our preliminary findings were encouraging and supports further research in a large randomized trial to evaluate the efficacy of such method, in refractory and advanced solid tumors.

Download Full-text

Emergency department visits among patients with advanced solid tumors at a cancer center in Mexico City.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.34_suppl.52 ◽

2018 ◽

Vol 36 (34_suppl) ◽

pp. 52-52

Author(s):

Miguel Araujo ◽

Mirza Alcalde Castro ◽

Enrique Soto Perez De Celis ◽

Andrea De la O ◽

Rafael Reyes ◽

...

Keyword(s):

Emergency Department ◽

Solid Tumors ◽

Mexico City ◽

Advanced Cancer ◽

Palliative Chemotherapy ◽

Emergency Department Visits ◽

Cancer Center ◽

Advanced Solid Tumors ◽

Newly Diagnosed ◽

Ed Visits

52 Background: Emergency department (ED) visits are a distressing event for patients with advanced cancer, and identifying planned, unplanned and avoidable ED visits is important for providing better cancer care. We studied the causes for ED visits, as well as potentially avoidable ED visits during palliative chemotherapy, among patients with advanced cancer treated at a public cancer center in Mexico City. Methods: Consecutive patients with newly diagnosed advanced solid tumors treated at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán from 10/2015 to 03/2016 were screened. Patients who visited the ED during that period were included, and their demographic and clinical characteristics recorded. Number and reasons for ED visits were obtained from medical records. Among patients who received chemotherapy within the previous 30 days, the following reasons for ED visits were classified as avoidable: anemia, nausea, dehydration, neutropenia, diarrhea, pain, emesis, pneumonia, fever or sepsis (according to Centers for Medicare and Medicare Services Hospital Outpatient Quality Reporting Program). Results: 77 patients were diagnosed with advanced solid tumors during the study period, of which 53 (69%) had at least one ED visit. Median age was 63 years (range, 19-88), and 47% were men (n = 25). 51% had gastrointestinal, 21% genitourinary and 28% other tumors. Median follow-up was 360 days. 95 ED visits were identified; with a median number of ED visits per patient of 1 (range 1-5). The most common causes of ED visits were: infections (n = 20; 21%), gastrointestinal disorders (n = 18; 19%), pain (n = 15; 16%), ascites (n = 14; 15%), anemia (n = 4; 4%), catheter dysfunction (n = 4; 4%), and other causes (n = 20; 21%). 57% of ED visits among patients who received chemotherapy within the previous 30 days were classified as potentially avoidable. Conclusions: Over two thirds of patients with newly diagnosed metastatic cancer had ED visits in the first year after diagnosis. Furthermore, more than a half of ED visits among patients receiving palliative chemotherapy were potentially avoidable. Strategies aimed at reducing ED visits are needed to improve quality of care for patients with advanced cancer.

Download Full-text